Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Faria, L. C., Gigou, M., Roque-Afonso, A. M., Sebagh, M., Roche, B., Fallot, G., Ferrari, T. C., Guettier, C., Dussaix, E., Castaing, D., Brechot, C., & Samuel, D. Gastroenterology, 134(7):1890–9; quiz 2155, June, 2008. abstract bibtex BACKGROUND & AIMS: Hepatitis B virus (HBV) recurrence after orthotopic liver transplantation (OLT) is significantly reduced by prophylaxis with hyperimmune antibody to hepatitis B surface antigen (anti-HBs) globulins (HBIG) and antiviral drugs. The role of hepatocellular carcinoma (HCC) in HBV recurrence remains unclear. We investigated the association between HCC pre-OLT and HBV recurrence post-OLT. METHODS: We studied 99 hepatitis B surface antigen-positive patients who underwent OLT for cirrhosis. The median follow-up period was 43 months. All patients received HBIG, and 51 also received lamivudine and/or adefovir. Of these 99 patients, 31 had HCC before OLT. Total HBV DNA and covalently closed circular (ccc)-DNA were measured in tumor and nontumor tissues from the explanted livers of 16 of these 31 HCC patients and, also, in a context of tumor recurrence, in 3 patients who developed HBV/HCC recurrence. RESULTS: Fourteen patients (14.1%) developed HBV recurrence within a median period of 15 months post-OLT. HCC at OLT, a pre-OLT HBV DNA viral load \textgreater or = 100,000 copies/mL, and HBIG monoprophylaxis were independently associated with HBV recurrence post-OLT. Eleven out of the 31 patients with HCC at OLT presented with HBV recurrence and 3 out of the 68 patients without HCC had HBV recurrence (P \textless .0001). HBV recurrence was more frequent in patients who developed HCC recurrence (7/8 patients, 87.5%) than in those who did not (4/23 patients, 17.4%) (P \textless .0001). In the 16 explanted livers, cccDNA was detectable in HCC cells in 11 and in nontumor cells in 12. cccDNA was detected in a context of HCC recurrence in 2 of the 3 patients tested who developed HBV/HCC recurrence. CONCLUSIONS: The associations of HCC pre-OLT, and HCC recurrence with HBV recurrence post-OLT, and the detection of HBV DNA and cccDNA in HCC suggest that HBV replication in tumor cells may contribute to HBV recurrence post-OLT.
@article{faria_hepatocellular_2008,
title = {Hepatocellular carcinoma is associated with an increased risk of hepatitis {B} virus recurrence after liver transplantation},
volume = {134},
issn = {1528-0012 (ELECTRONIC); 0016-5085 (LINKING)},
shorttitle = {Hepatocellular carcinoma is associated with an increased risk of hepatitis {B} virus recurrence after liver transplantation},
abstract = {BACKGROUND \& AIMS: Hepatitis B virus (HBV) recurrence after orthotopic liver transplantation (OLT) is significantly reduced by prophylaxis with hyperimmune antibody to hepatitis B surface antigen (anti-HBs) globulins (HBIG) and antiviral drugs. The role of hepatocellular carcinoma (HCC) in HBV recurrence remains unclear. We investigated the association between HCC pre-OLT and HBV recurrence post-OLT. METHODS: We studied 99 hepatitis B surface antigen-positive patients who underwent OLT for cirrhosis. The median follow-up period was 43 months. All patients received HBIG, and 51 also received lamivudine and/or adefovir. Of these 99 patients, 31 had HCC before OLT. Total HBV DNA and covalently closed circular (ccc)-DNA were measured in tumor and nontumor tissues from the explanted livers of 16 of these 31 HCC patients and, also, in a context of tumor recurrence, in 3 patients who developed HBV/HCC recurrence. RESULTS: Fourteen patients (14.1\%) developed HBV recurrence within a median period of 15 months post-OLT. HCC at OLT, a pre-OLT HBV DNA viral load {\textgreater} or = 100,000 copies/mL, and HBIG monoprophylaxis were independently associated with HBV recurrence post-OLT. Eleven out of the 31 patients with HCC at OLT presented with HBV recurrence and 3 out of the 68 patients without HCC had HBV recurrence (P {\textless} .0001). HBV recurrence was more frequent in patients who developed HCC recurrence (7/8 patients, 87.5\%) than in those who did not (4/23 patients, 17.4\%) (P {\textless} .0001). In the 16 explanted livers, cccDNA was detectable in HCC cells in 11 and in nontumor cells in 12. cccDNA was detected in a context of HCC recurrence in 2 of the 3 patients tested who developed HBV/HCC recurrence. CONCLUSIONS: The associations of HCC pre-OLT, and HCC recurrence with HBV recurrence post-OLT, and the detection of HBV DNA and cccDNA in HCC suggest that HBV replication in tumor cells may contribute to HBV recurrence post-OLT.},
number = {7},
journal = {Gastroenterology},
author = {Faria, L. C. and Gigou, M. and Roque-Afonso, A. M. and Sebagh, M. and Roche, B. and Fallot, G. and Ferrari, T. C. and Guettier, C. and Dussaix, E. and Castaing, D. and Brechot, C. and Samuel, D.},
month = jun,
year = {2008},
keywords = {Adenine/analogs \& derivatives/therapeutic use Adolescent Adult Aged Antiviral Agents/therapeutic use Carcinoma, Circular/analysis DNA, DNA Time Factors Treatment Outcome Viral Load Virus Replication, Hepatocellular/drug therapy/surgery/ virology DNA},
pages = {1890--9; quiz 2155},
}
Downloads: 0
{"_id":"Ko7Y3cNCfra4b4ejd","bibbaseid":"faria-gigou-roqueafonso-sebagh-roche-fallot-ferrari-guettier-etal-hepatocellularcarcinomaisassociatedwithanincreasedriskofhepatitisbvirusrecurrenceafterlivertransplantation-2008","author_short":["Faria, L. C.","Gigou, M.","Roque-Afonso, A. M.","Sebagh, M.","Roche, B.","Fallot, G.","Ferrari, T. C.","Guettier, C.","Dussaix, E.","Castaing, D.","Brechot, C.","Samuel, D."],"bibdata":{"bibtype":"article","type":"article","title":"Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation","volume":"134","issn":"1528-0012 (ELECTRONIC); 0016-5085 (LINKING)","shorttitle":"Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation","abstract":"BACKGROUND & AIMS: Hepatitis B virus (HBV) recurrence after orthotopic liver transplantation (OLT) is significantly reduced by prophylaxis with hyperimmune antibody to hepatitis B surface antigen (anti-HBs) globulins (HBIG) and antiviral drugs. The role of hepatocellular carcinoma (HCC) in HBV recurrence remains unclear. We investigated the association between HCC pre-OLT and HBV recurrence post-OLT. METHODS: We studied 99 hepatitis B surface antigen-positive patients who underwent OLT for cirrhosis. The median follow-up period was 43 months. All patients received HBIG, and 51 also received lamivudine and/or adefovir. Of these 99 patients, 31 had HCC before OLT. Total HBV DNA and covalently closed circular (ccc)-DNA were measured in tumor and nontumor tissues from the explanted livers of 16 of these 31 HCC patients and, also, in a context of tumor recurrence, in 3 patients who developed HBV/HCC recurrence. RESULTS: Fourteen patients (14.1%) developed HBV recurrence within a median period of 15 months post-OLT. HCC at OLT, a pre-OLT HBV DNA viral load \\textgreater or = 100,000 copies/mL, and HBIG monoprophylaxis were independently associated with HBV recurrence post-OLT. Eleven out of the 31 patients with HCC at OLT presented with HBV recurrence and 3 out of the 68 patients without HCC had HBV recurrence (P \\textless .0001). HBV recurrence was more frequent in patients who developed HCC recurrence (7/8 patients, 87.5%) than in those who did not (4/23 patients, 17.4%) (P \\textless .0001). In the 16 explanted livers, cccDNA was detectable in HCC cells in 11 and in nontumor cells in 12. cccDNA was detected in a context of HCC recurrence in 2 of the 3 patients tested who developed HBV/HCC recurrence. CONCLUSIONS: The associations of HCC pre-OLT, and HCC recurrence with HBV recurrence post-OLT, and the detection of HBV DNA and cccDNA in HCC suggest that HBV replication in tumor cells may contribute to HBV recurrence post-OLT.","number":"7","journal":"Gastroenterology","author":[{"propositions":[],"lastnames":["Faria"],"firstnames":["L.","C."],"suffixes":[]},{"propositions":[],"lastnames":["Gigou"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Roque-Afonso"],"firstnames":["A.","M."],"suffixes":[]},{"propositions":[],"lastnames":["Sebagh"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Roche"],"firstnames":["B."],"suffixes":[]},{"propositions":[],"lastnames":["Fallot"],"firstnames":["G."],"suffixes":[]},{"propositions":[],"lastnames":["Ferrari"],"firstnames":["T.","C."],"suffixes":[]},{"propositions":[],"lastnames":["Guettier"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Dussaix"],"firstnames":["E."],"suffixes":[]},{"propositions":[],"lastnames":["Castaing"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Brechot"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Samuel"],"firstnames":["D."],"suffixes":[]}],"month":"June","year":"2008","keywords":"Adenine/analogs & derivatives/therapeutic use Adolescent Adult Aged Antiviral Agents/therapeutic use Carcinoma, Circular/analysis DNA, DNA Time Factors Treatment Outcome Viral Load Virus Replication, Hepatocellular/drug therapy/surgery/ virology DNA","pages":"1890–9; quiz 2155","bibtex":"@article{faria_hepatocellular_2008,\n\ttitle = {Hepatocellular carcinoma is associated with an increased risk of hepatitis {B} virus recurrence after liver transplantation},\n\tvolume = {134},\n\tissn = {1528-0012 (ELECTRONIC); 0016-5085 (LINKING)},\n\tshorttitle = {Hepatocellular carcinoma is associated with an increased risk of hepatitis {B} virus recurrence after liver transplantation},\n\tabstract = {BACKGROUND \\& AIMS: Hepatitis B virus (HBV) recurrence after orthotopic liver transplantation (OLT) is significantly reduced by prophylaxis with hyperimmune antibody to hepatitis B surface antigen (anti-HBs) globulins (HBIG) and antiviral drugs. The role of hepatocellular carcinoma (HCC) in HBV recurrence remains unclear. We investigated the association between HCC pre-OLT and HBV recurrence post-OLT. METHODS: We studied 99 hepatitis B surface antigen-positive patients who underwent OLT for cirrhosis. The median follow-up period was 43 months. All patients received HBIG, and 51 also received lamivudine and/or adefovir. Of these 99 patients, 31 had HCC before OLT. Total HBV DNA and covalently closed circular (ccc)-DNA were measured in tumor and nontumor tissues from the explanted livers of 16 of these 31 HCC patients and, also, in a context of tumor recurrence, in 3 patients who developed HBV/HCC recurrence. RESULTS: Fourteen patients (14.1\\%) developed HBV recurrence within a median period of 15 months post-OLT. HCC at OLT, a pre-OLT HBV DNA viral load {\\textgreater} or = 100,000 copies/mL, and HBIG monoprophylaxis were independently associated with HBV recurrence post-OLT. Eleven out of the 31 patients with HCC at OLT presented with HBV recurrence and 3 out of the 68 patients without HCC had HBV recurrence (P {\\textless} .0001). HBV recurrence was more frequent in patients who developed HCC recurrence (7/8 patients, 87.5\\%) than in those who did not (4/23 patients, 17.4\\%) (P {\\textless} .0001). In the 16 explanted livers, cccDNA was detectable in HCC cells in 11 and in nontumor cells in 12. cccDNA was detected in a context of HCC recurrence in 2 of the 3 patients tested who developed HBV/HCC recurrence. CONCLUSIONS: The associations of HCC pre-OLT, and HCC recurrence with HBV recurrence post-OLT, and the detection of HBV DNA and cccDNA in HCC suggest that HBV replication in tumor cells may contribute to HBV recurrence post-OLT.},\n\tnumber = {7},\n\tjournal = {Gastroenterology},\n\tauthor = {Faria, L. C. and Gigou, M. and Roque-Afonso, A. M. and Sebagh, M. and Roche, B. and Fallot, G. and Ferrari, T. C. and Guettier, C. and Dussaix, E. and Castaing, D. and Brechot, C. and Samuel, D.},\n\tmonth = jun,\n\tyear = {2008},\n\tkeywords = {Adenine/analogs \\& derivatives/therapeutic use Adolescent Adult Aged Antiviral Agents/therapeutic use Carcinoma, Circular/analysis DNA, DNA Time Factors Treatment Outcome Viral Load Virus Replication, Hepatocellular/drug therapy/surgery/ virology DNA},\n\tpages = {1890--9; quiz 2155},\n}\n\n","author_short":["Faria, L. C.","Gigou, M.","Roque-Afonso, A. M.","Sebagh, M.","Roche, B.","Fallot, G.","Ferrari, T. C.","Guettier, C.","Dussaix, E.","Castaing, D.","Brechot, C.","Samuel, D."],"key":"faria_hepatocellular_2008","id":"faria_hepatocellular_2008","bibbaseid":"faria-gigou-roqueafonso-sebagh-roche-fallot-ferrari-guettier-etal-hepatocellularcarcinomaisassociatedwithanincreasedriskofhepatitisbvirusrecurrenceafterlivertransplantation-2008","role":"author","urls":{},"keyword":["Adenine/analogs & derivatives/therapeutic use Adolescent Adult Aged Antiviral Agents/therapeutic use Carcinoma","Circular/analysis DNA","DNA Time Factors Treatment Outcome Viral Load Virus Replication","Hepatocellular/drug therapy/surgery/ virology DNA"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"http://bibbase.org/zotero/biblioial","dataSources":["ftoP3zPyb2N3b9Noc"],"keywords":["adenine/analogs & derivatives/therapeutic use adolescent adult aged antiviral agents/therapeutic use carcinoma","circular/analysis dna","dna time factors treatment outcome viral load virus replication","hepatocellular/drug therapy/surgery/ virology dna"],"search_terms":["hepatocellular","carcinoma","associated","increased","risk","hepatitis","virus","recurrence","liver","transplantation","faria","gigou","roque-afonso","sebagh","roche","fallot","ferrari","guettier","dussaix","castaing","brechot","samuel"],"title":"Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation","year":2008}